Quantitative Benefit-Risk Assessment: State of the Practice Within Industry.

Smith, Meredith Y; van Til, Janine; DiSantostefano, Rachael L; Hauber, A Brett; Marsh, Kevin

Smith, Meredith Y; van Til, Janine; DiSantostefano, Rachael L; Hauber, A Brett; Marsh, Kevin.

Afiliación

Smith MY; Alexion Pharmaceuticals, Inc., 121 Seaport Boulevard, Boston, MA, 02210, USA. meredith.smith@alexion.com.
van Til J; Department of Regulatory and Quality Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA, 90089, USA. meredith.smith@alexion.com.
DiSantostefano RL; University of Twente, Enschede, Netherlands.
Hauber AB; Janssen R&D, LLC., Titusville, NJ, USA.
Marsh K; RTI-Health Solutions, Research Triangle Park, NC, USA.

Ther Innov Regul Sci ; 55(2): 415-425, 2021 03.

Article en En | MEDLINE | ID: mdl-33111177

Asunto(s)

Comunicación; Industrias; Liderazgo; Proyectos Piloto; Medición de Riesgo

Palabras clave

Benefitrisk framework; Discrete choice experiment; Medical devices; Medicinal products; Multi-criteria decision analysis; Structured benefitrisk assessment

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Comunicación / Industrias Tipo de estudio: Etiology_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies Idioma: En Revista: Ther Innov Regul Sci Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google